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INTRODUCTION
Over the past 35 years, the world has seen the emergence or reemergence of more than 30 human viruses, including HIV-1, HIV-2, West Nile virus, severe acute respiratory syndrome (SARS) coronavirus, and most recently, H1N1 influenza virus (1) . Our understanding of viral evolution and pathogenesis, as well as our ability to combat viruses with rationally designed therapeutic agents, relies on a molecular-level knowledge of the mechanisms by which viruses redirect normal cellular resources for the purpose of viral replication. Most viruses have evolved to accomplish the task of hijacking cellular machinery through targeted interactions between their own proteins and those of their host. Although the interactions between viral and host-cell proteins are often difficult to elucidate experimentally, the primary structures of viral proteins hold direct clues in the form of short, linear protein motifs. Such linear amino acid residue signatures can serve as molecular beacons for various protein-protein interactions, which often result in posttranslational modification (PTM) of proteins, proteolytic cleavage, and altered protein localization (2) .
Among the most widely studied motifs are those that mediate protein phosphorylation by kinases. To date, about one-fifth of the 518 human kinases have known associated motifs (3) . Typically, these motifs are represented as linear sequence patterns by the single-letter abbreviations for the 20 amino acids. For example, the phosphorylation motif of the kinase Akt can be described by the pattern RxRxx[ST __ ], where "x" denotes any amino acid residue, the underlined residues denote the phosphorylation site, and the brackets indicate that the kinase can phosphorylate either serine (S) or threonine (T) residues.
The chemical and structural diversity afforded by protein phosphorylation is used by nearly all cellular processes, with deficiencies in phosphorylation contributing to various human diseases (4) . Due to technological advances in both enrichment strategies and high-throughput peptide sequencing by tandem mass spectrometry, the number of known phosphorylation sites across all studied species has grown exponentially over the past decade. To date, the literature cites more than 100,000 phosphorylation sites from organisms representing all domains of life. In response to the increase in the number of known phosphorylation sites, various phosphorylation site databases have emerged (5) (6) (7) (8) (9) (10) (11) (12) (13) . These databases serve as organism-specific repositories for phosphorylation data and enable the research community to better assess the current state of knowledge.
Many viruses have evolved to use phosphorylation as a means of enhancing viral replication and inhibiting normal cellular functions, which has led to explorations of human kinases as potential antiviral drug targets (14) . Phosphorylation in viruses is most often achieved through the action of host-cell kinases, although some viral families (for example, herpesviruses) encode their own protein kinases. Although specific phosphorylation sites on the most widely studied human viral proteins were uncovered starting in the mid 1980s, databases of viral phosphorylation sites have yet to be created. Thus, the extent of viral phosphorylation across all human virus families has been difficult to assess. Additionally, the widespread use of low-throughput techniques in the discovery and confirmation of phosphorylation sites in viral proteins suggests that most sites likely remain undiscovered.
Here, we addressed two of the aforementioned deficiencies. First, we compiled the first database of viral phosphorylation sites. Second, from a large collection of known human phosphorylation sites (n = 24,293) gathered from various databases, in conjunction with the scan-x prediction tool (15), we have performed the first high-specificity prediction of viral phosphorylation sites in viruses that infect humans. By cross-validating these prediction results against our literature-based viral phosphorylation database, we were also able to extrapolate a minimum expected number of phosphorylation sites across all sequenced human viruses. review of 229 viruses and virus families known to replicate in human hosts. The database currently contains 329 unique viral phosphorylation sites on 111 proteins from 52 viruses and is composed of precisely localized sites detected both in vivo and in vitro. In total, 150 journal references were used to curate the database. Phosphorylation sites that are known to occur, but that have not been precisely localized, were not included in the present version of virPTM. Each entry in the database contains (i) the virus name, (ii) the viral protein name, (iii) the viral protein sequence, (iv) the site of the modification, (v) the local primary structure (that is, seven amino acid residues upstream and downstream of the modification site), and (vi) the reference in which experimental detection of the site is described. In addition to existing in its entirety online (http://virptm.hms.harvard.edu), the entries of the database (with the exception of whole-protein sequences) are provided here (table S1) .
Inspection of the virPTM database indicates the steady increase in the number of literature-based phosphorylation sites in human viruses between 1986 and the present (Fig. 1) . Forty percent of all precisely localized viral phosphorylation sites come from the following five well-studied viruses: human herpesvirus 4 (HHV-4; 32 sites on seven proteins), human adenovirus 5 (HAdV-5; 27 sites on six proteins), HHV-1 (26 sites on nine proteins), HIV-1 (25 sites on nine proteins), and HHV-5 (24 sites on five proteins) ( Table 1 ). At present, the virPTM database contains 250 serine phosphorylation sites (76% of the total), 65 threonine phosphorylation sites (20%), and 14 tyrosine phosphorylation sites (4%). Because most viruses do not encode their own protein kinases, most sites contained within virPTM are expected to be the result of phosphorylation by human kinases; however, the database also contains 14 sites that are phosphorylated by viral kinases and 11 sites that are autophosphorylated by viral kinases.
Prediction of viral phosphorylation sites with scan-x
Because the number of experimentally verified phosphorylation sites in human viruses that are contained within virPTM likely represents only a small fraction of all viral phosphorylation sites, much experimental work is needed to uncover the complete phosphoproteome of human viruses.
Testing each serine, threonine, and tyrosine residue for phosphorylation on candidate viral proteins is often prohibitive; therefore, a means to prioritize sites with a higher likelihood of phosphorylation is required. To this end, we have also included the results of our high-confidence human phosphorylation predictor, scan-x (15), on the virPTM Web site (the complete set of predictions is also provided in table S2). By running scan-x on the complete set of 229 human viral proteomes (which consist of 3744 proteins) available from the National Center for Biotechnology Information (NCBI) Web site (http://www.ncbi.nlm.nih.gov/sites/genome/), we predicted 6723 high-confidence serine and threonine phosphorylation sites and 3202 high-confidence tyrosine phosphorylation sites on 2881 viral proteins. These results provide the residues with the highest likelihood of modification (as deemed by scan-x) in the total set of 211,018 serine, threonine, and tyrosine residues contained within all human viral proteins. Because each potential modification site is given a scan-x score, these sites may be further prioritized by investigators to yield predictions even beyond the high-specificity thresholds used in our analyses.
Sensitivity and specificity of scan-x on viral data
Although extensive cross-validation was performed during the development of the scan-x tool, and its improved performance relative to other human phosphoprediction software has been described previously (15) , we sought to assess the expected predictive performance of scan-x in the context of viral phosphorylation data. The assessment of a predictive tool such as scan-x typically involves calculations of sensitivity and specificity. In the present application, sensitivity can be described as the proportion of phosphorylation sites called "positive" by the predictor relative to all known phosphorylation sites, whereas specificity can be described as the proportion of phosphorylation sites called "negative" by the predictor relative to all known unphosphorylated sites. Thus, accurate calculations of sensitivity and specificity require lists of known phosphorylated and unphosphorylated sites, which effectively serve as positive and negative controls for the method. Such lists were obtained with the sequence information already contained in the virPTM database.
For the positive control, we started with the complete set of 329 known literature-based phosphorylation sites. Because scan-x requires a minimum of seven residues on each side of the phosphorylation site to make a prediction, phosphorylation sites in the database that were within seven residues of the N or C terminus were removed. Furthermore, given that scan-x predictions are based on the human kinome, viral phosphorylation sites that are the result of virally encoded kinases were also removed. After this filtering procedure, 284 viral phosphorylation sites remained, including 272 serine and threonine and 12 tyrosine phosphorylation sites (table  S3) . This positive control data set enabled us to compute the sensitivity of scan-x on viral phosphorylation data. scan-x correctly predicted 116 of the 272 serine and threonine phosphorylation sites, thus yielding a serine and threonine phosphorylation sensitivity of 42.6%. With regard to the tyrosine data, scan-x correctly predicted 9 of the 12 sites, thus yielding a tyrosine phosphorylation sensitivity of 75.0% (Table 2) .
Computing the specificity of scan-x with respect to viral phosphorylation data required a list of unphosphorylated serine, threonine, and tyrosine residues (that is, negative phosphorylation sites) to serve as a negative control; however, obtaining such a list of unphosphorylated residues is difficult for several reasons. First, one cannot be certain that a particular residue does not get phosphorylated under all possible cellular conditions, and second, viral phosphorylation has not been comprehensively studied to date. To overcome these challenges, we used a proxy for negative phosphorylation sites on the basis of the assumption that most serine, threonine, and tyrosine residues in viral proteins remain in an unphosphorylated state. Thus, all serine, threonine, and tyrosine residues from previously studied viral proteins bearing at least one phosphorylation site, but not previously shown to be phosphorylated, were used as negative phosphorylation sites.
It should be noted a priori, however, that this approach is conservative given that a percentage of the sites deemed negative are in fact true phosphorylation sites that have yet to be identified. With the proxy, calculated values of specificity represent the lower bound on the true specificity of the scan-x methodology. This approach resulted in 5360 negative serine and threonine phosphorylation sites and 1040 negative tyrosine phosphorylation sites among the viral proteins in the virPTM database (table S3) . Among these, scan-x incorrectly predicted 383 serine and threonine phosphorylation sites and 96 tyrosine phosphorylation sites, thus yielding specificities of 92.9 and 90.9%, respectively. However, as mentioned earlier, we can reasonably assume that some percentage of these incorrectly predicted phosphorylation sites are in fact true phosphorylation sites, which suggests that the actual specificities of scan-x are greater than the reported values.
Description of the virPTM version 1.0 Web site
The virPTM Web site is intended to serve as a dynamic repository for the research community of PTM sites in viral proteins. At present, the Web site contains information on viral phosphorylation sites; however, additional viral PTMs are expected to be added in the future. The Web site can be subdivided into two main sections: (i) literature-based viral phosphorylation sites and (ii) scan-x viral phosphorylation predictions. Links to both of these sections are visible on the main Web site page. The main page also contains a link to the positive and negative control data sets that were used to evaluate the sensitivity and specificity of the scan-x predictor. Clicking on the "literature-based viral phosphorylation sites" link on the main page enables users to view the experimentally validated phosphorylation sites contained in the database that have been collated from the literature (Fig. 2A) . The viruses are sorted alphabetically by their acronyms.
The format of the entries is the same as shown here (Table 1 and table S1 ), but also includes links to the complete protein sequence and the corresponding reference for the phosphorylation site in PubMed. Phosphorylation sites are highlighted in red with dashes indicating the N or C terminus of a protein. Asterisks in the "Residue & Position" column of the database denote phosphorylation sites that are due to virally encoded kinases.
To access the predictive section of the virPTM Web site, users should click on the "scan-x viral phosphorylation predictions" link, which provides an alphabetically sorted list of the 229 viruses known to replicate in human cells about which phosphorylation predictions have been made. Clicking on the name of a virus opens a new Web page that contains the scan-x prediction results for that virus (see screenshot in Fig. 2B ). The scan-x prediction results page can be divided into two regions. A list of viral proteins about which phosphorylation predictions have been made is enclosed in two horizontal lines below the heading of the page. Each protein has a total score (equal to the sum of all site-specific scores on the protein) and a maximum score (equal to the highest-scoring predicted site on the protein) located beside it. Proteins on the scan-x results page are sorted according to their maximum score. Numbered links beside each protein, which represent the overall rank of the protein in the entire viral prediction data set, enable users to jump down to the prediction results for that protein. The virPTM logo in the upper right-hand corner of the screen provides a link back to the main virPTM Web page.
On a sample screenshot of the scan-x prediction results for the NP-1 protein of the human bocavirus, the numbers "164/2881" indicate that a predicted phosphorylation site had the 164th highest maximum scan-x score among the total set of 2881 viral proteins that were scanned (Fig. 2C) . The numbers "186.167" and "29.560" indicate the total and maximum scan-x scores on the protein, respectively. Predicted phosphorylation sites correspond to the central residues of the 15-amino acid peptides located beneath the viral protein sequence. The number after the 15-amino acid peptide sequence indicates the scan-x score of the peptide. The number in parentheses after the scan-x score indicates the position of the predicted phosphorylation site in the context of the overall protein sequence. Residues in the 15-amino acid peptides may be colored green, red, or blue. Green residues indicate a positive contribution to the overall prediction, whereas red residues indicate a negative contribution to the overall prediction. Blue residues highlight the motif-x-derived phosphorylation motif under which the prediction was made. Phosphorylation sites may be predicted with multiple motifs. Thus, Ser 18 in the NP-1 protein of human bocavirus is predicted to be phosphorylated under the RxxS, SP, RxxSP, SPxR, and SPxxxxxK motifs (Fig.  2C) . Viewing the overall prediction results for the NP-1 protein indicates seven total phosphorylation sites predicted by scan-x including Ser . Although no specific phosphorylation sites have been previously mapped to the NP-1 protein of human bocavirus, phosphorylation of the homologous NP-1 protein in bovine parvovirus (from which human bocavirus partially derives its name: bovine-canine virus) has been known for more than two decades (16) , thus lending support to the scan-x phosphorylation predictions for this protein.
DISCUSSION
Given the recent increase in the amount of phosphorylation data because of protein sequencing enabled by tandem mass spectrometry, various general and organism-specific phosphorylation databases have emerged (5) (6) (7) (8) (9) (10) (11) (12) (13) ). Yet, in the field of human virology, no such resource has previously been compiled. To address this need, we have collated a database of in vitro and in vivo viral phosphorylation sites based on a thorough literature review. The database currently contains information on precisely localized phosphorylation sites in viruses known to infect humans; however, it should be 
*Bold residues denote phosphorylation sites and hyphens denote protein termini. considered a work in progress. Future improvements to the database are likely to consist of (i) the inclusion of other PTMs that act on viral proteins (for example, acetylation, glycosylation, and SUMOylation, among others); (ii) the inclusion of proteins that are modified but whose sites of modification have not been determined; (iii) the inclusion of viruses that infect hosts other than humans; and (iv) notes on the conditions under which the modifications were detected (whether in vivo or in vitro, identifying the modifying kinase involved, etc.). Because viral phosphorylation sites can often provide unique insights into interacting host proteins due to their motif signatures, high-confidence predictions of viral phosphorylation sites may be used to better understand the biological pathways exploited by these disease-causing agents. To this end, we have also provided the research community with the first database of predicted viral phosphorylation sites with the scan-x algorithm. Because no viral phosphorylation sites were used in the training of the scan-x predictor, the literature-based viral phosphorylation sites contained within the virPTM database served as an unbiased test set to characterize the sensitivity and specificity of the scan-x tool on viral phosphorylation data. Furthermore, this data set may also be used to benchmark existing and future human phosphorylation prediction software. The virPTM Web site provides a set of positive and presumed negative phosphorylation sites, which will be regularly updated.
R E S E A R C H R E S O U R C E
The evaluation of the scan-x predictor with literature-based viral phosphorylation sites contained in the virPTM database has also provided the ability to extrapolate the breadth of viral protein phosphorylation more generally. In the total set of 229 human viral proteomes, scan-x predicted 6723 serine and threonine phosphorylation sites and 3202 tyrosine phosphorylation sites. Assuming the same sensitivity and specificity levels achieved in the literature-based data, we can expect that of these sites, at a minimum, 1563 serine and threonine residues and 274 tyrosine residues are correctly assigned as phosphorylated by scan-x. We can further extrapolate that a minimum of 3677 serine and threonine and 365 tyrosine phosphorylation sites should currently exist on all proteins from human viruses (see Materials and Methods), most of which (>90%) remain undiscovered. Whereas these statistics suggest that, at worst, only 23% (that is, 1563 of 6723) of the scan-x serine and threonine predictions and 9% (274 of 3202) of the scan-x tyrosine predictions may be correct, when compared to the expected odds of identifying phosphorylated serine and threonine, as well as tyrosine residues at random in all viral proteins (2 and 1%, respectively), the utility of scan-x is apparent.
Finally, because scan-x operates at the level of phosphorylation sequence motifs (often unique to kinases or kinase families), the inference of the modifying kinase for known or predicted phosphorylation sites can also potentially be made. A proof of principle is provided by simian virus 40 (SV40), which contains 13 annotated phosphorylation sites in the virPTM database (8 of which were correctly predicted by scan-x), as well as an additional 10 scan-x serine and threonine phosphorylation predictions that have yet to be validated. Among the complete list of 23 known and predicted serine and threonine phosphorylation sites are 6 sites (23%) that conform to an "SQ" motif, a known phosphorylation signature for the kinase ataxia-telangiectasia mutated (ATM). The large proportion of SQ motifs on SV40 proteins suggests that ATM might be an important interacting protein for SV40. That previous research has demonstrated that ATM controls the replication of SV40 in vivo (17) lends strong support to the notion that known and predicted phosphorylation motifs on viral proteins may be used as starting points to explore and understand interactions between viral proteins and host kinases. Although the present study has dealt exclusively with phosphorylation, the concept of exploring viral primary structure as a means of synthesizing hypotheses regarding viral-host interactions is broadly generalizable and may ultimately be used in the rational design and testing of antiviral drugs.
MATERIALS AND METHODS

Curation of the virPTM database
To find the subset of viruses with sequenced genomes and proteomes that are able to replicate in human hosts, we started with a complete list of sequenced viruses (n = 2947) from the NCBI Web site (http://www.ncbi.nlm. nih.gov/genomes/genlist.cgi?taxid=10239&type=5&name=Viruses) and performed literature searches to determine the host range of each virus. This analysis resulted in the retrieval of 229 viruses (and viral proteomes) that are able to replicate in human cells, which represented a starting point for further data mining. The virPTM database was then collated through directed Internet searches on Google, PubMed, and various scientific journal Web sites with keywords specific to each of the 229 human viruses (for example, virus name) and the subject of protein phosphorylation (for example, "kinase," "phosphorylation," "phosphorylation site," etc.). Retrieved journal articles were also further mined for relevant citations relating to viral phosphorylation. Phosphorylation sites were only added to the database if the experimental evidence unambiguously localized the site of modification. For example, if the mutation of two adjacent potential phosphorylation sites showed a decrease in the overall extent of protein phosphorylation, but these sites were not disambiguated individually, then neither site was included in the database. Amino acid sequences of proteins bearing phosphorylation sites that are contained in the virPTM database were preferentially obtained directly from the reference (if published) or from the reference sequence for the viral protein obtained on the NCBI or the ViralZone Web site (http://www.expasy.ch/viralzone/). So as not to introduce bias, all decisions regarding the inclusion of specific phosphorylation sites in the virPTM database were made blind with regard to their prediction status by scan-x. In cases in which the same modification site was detected by multiple references, the reference with the earliest publication date was used in the database. The process of collation was performed until repeated Internet or literature searches yielded no additional phosphorylation sites beyond those already included in the database. The online version of the database will be updated periodically.
Prediction of viral phosphorylation sites
All viral phosphorylation sites predicted in the present study (that is, from the virPTM database, from whole proteomes of human viruses, or from the proteins on which at least one literature-based phosphorylation site was detected) were predicted with the previously described human scan-x predictor (15) . Briefly, the scan-x predictor works by scanning the motifs extracted by motif-x (18) from a large database (n = 24,293) of human serine, threonine, and tyrosine phosphorylation sites against a sequence of interest, thus deriving a scan-x score. Details of the scan-x scoring procedure and the list of human motifs used in the creation of the scan-x predictor were provided previously (15) . Serine and threonine sites matching a motif with at least three fixed positions, two fixed positions, or one fixed position (including the central residue) that received minimum scan-x scores of 2.2, 12.2, or 42.2, respectively, were deemed predicted serine and threonine phosphorylation sites. Similarly, tyrosine sites matching a motif with at least three fixed positions, two fixed positions, or one fixed position (including the central residue) that received minimum scan-x scores of −3.3, 6.7, or 36.7, respectively, were deemed predicted tyrosine phosphorylation sites. The aforementioned scan-x score cutoffs were used because they corresponded to the 95% specificity level by a 10-fold cross-validation procedure performed on the human phosphorylation data set (15) .
Sensitivity, specificity, and projection calculations
Sensitivity was calculated as (number of true positives)/(number of true positives + number of false negatives), and specificity was calculated as (number of true negatives)/(number of true negatives + number of false positives). The minimum number of correct scan-x identifications was calculated by multiplying the total number of viral scan-x predictions by the positive predictive value [PPV = (number of true positives)/(number of true positives + number of false positives)], which was calculated with the virPTM data set. To project the minimum total number of expected phosphorylation events in all human viruses, we divided the minimum number of correct scan-x identifications by the sensitivity (calculated with the virPTM database). The expected odds of identifying a phosphorylated residue at random was calculated as the projected minimum number of total viral phosphorylation sites divided by the total number of residues that may be phosphorylated in all viral proteomes.
SUPPLEMENTARY MATERIALS
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